IFNG and neoplasm: It was found that the IDO1 inhibitor PF-06840003, when used in combination with anti-PD-L1, could induce a higher proportion of T cells secreting IFN-γ and the expression of the cytolytic enzyme granzyme A, thereby enhancing anti-tumor effects.